Simon Dominique
Department of Endocrinology and Diabetology, Hôpital Robert Debré, FR-75019 Paris, France.
Horm Res. 2009 Nov;72 Suppl 1:65-8. doi: 10.1159/000229767. Epub 2009 Nov 27.
Available data on growth hormone (GH) therapy in glucocorticoid-treated children with juvenile idiopathic arthritis (JIA) suggest a satisfactory safety profile. There have been few reports of adverse effects on the course of the joint disease (e.g., inflammatory flare-ups or osteoarticular complications). Despite strong concern that combined glucocorticoid and GH therapy might impair glucose tolerance, this has been uncommon in clinical trials. This article briefly reviews the published data and offers recommendations for monitoring patients with JIA who are receiving GH replacement therapy.
The safety of GH therapy in children receiving glucocorticoid therapy for JIA seems satisfactory with few serious adverse events reported to date; however, given the small number of treated patients and the short periods of follow-up in each individual patient, the decision to initiate GH therapy in patients receiving glucocorticoids should be made cautiously.
关于生长激素（GH）治疗糖皮质激素治疗的幼年特发性关节炎（JIA）患儿的数据表明其安全性良好。关于对关节疾病病程的不良反应（如炎症发作或骨关节并发症）的报道较少。尽管人们强烈担心糖皮质激素和GH联合治疗可能损害糖耐量，但在临床试验中这种情况并不常见。本文简要回顾已发表的数据，并为接受GH替代治疗的JIA患者的监测提供建议。
对于接受糖皮质激素治疗JIA的儿童，GH治疗的安全性似乎良好，迄今为止报告的严重不良事件较少；然而，鉴于接受治疗的患者数量较少且每位患者的随访时间较短，对于接受糖皮质激素治疗的患者启动GH治疗的决定应谨慎做出。
